Late Breaking Abstract - Phase 1 dose escalation study of aerosolized pirfenidone in normal healthy volunteers (NHV), smokers, and IPF patients

A. Montgomery (Seattle, United States of America), K. Otto (Seattle, United States of America), J. Khoo (Melbourne, Australia), I. Glaspole (Melbourne, Australia)

Source: International Congress 2018 – ILDs: From bench to bedside
Session: ILDs: From bench to bedside
Session type: Oral Presentation
Number: 266
Disease area: Airway diseases

Congress or journal article abstractSlide presentationE-posterWebcast

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
A. Montgomery (Seattle, United States of America), K. Otto (Seattle, United States of America), J. Khoo (Melbourne, Australia), I. Glaspole (Melbourne, Australia). Late Breaking Abstract - Phase 1 dose escalation study of aerosolized pirfenidone in normal healthy volunteers (NHV), smokers, and IPF patients. 266

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: